[CAS NO. 1393344-72-3] Varlilumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1393344-72-3]

Catalog

HY-P99057

Brand

MCE

CAS

1393344-72-3

DESCRIPTION [1393344-72-3]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Varlilumab]

For research use only. We do not sell to patients.

Summary

Varlilumab (CDX-1127) is a first-in-class human IgG1 anti- CD27 monoclonal antibody. Varlilumab has an anti-tumor activity ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02924038	Nicholas Butowski\|Celldex Therapeutics\|University of California, San Francisco	Glioma\|Malignant Glioma\|Astrocytoma, Grade II\|Oligodendroglioma\|Glioma, Astrocytic\|Oligoastrocytoma, Mixed	April 3, 2017	Phase 1
NCT02543645	Celldex Therapeutics\|Genentech, Inc.	Carcinoma, Renal Cell\|Kidney Diseases\|Kidney Neoplasms\|Urogenital Neoplasms\|Urologic Diseases\|Urologic Neoplasms\|Neoplasms by Histologic Type\|Neoplasms\|Clear-cell Metastatic Renal Cell Carcinoma\|Melanoma\|Triple Negative Breast Cancer\|Bladder Cancer\|Head and Neck Cancer\|Non-small Cell Lung Cancer	October 2015	Phase 1
NCT03617328	Craig L Slingluff, Jr\|Celldex Therapeutics\|University of Virginia	Melanoma	November 13, 2018	Phase 1\|Phase 2
NCT02413827	Celldex Therapeutics	Unresectable Stage III or Stage IV Melanoma	April 2015	Phase 1\|Phase 2
NCT01460134	Celldex Therapeutics	CD27 Expressing B-cell Malignancies for Example Hodgkin´s Lymphoma\|Chronic Lymphocytic Leukemia\|Mantle Cell Lymphoma\|Marginal Zone B Cell Lymphoma)\|Any T-cell Malignancy\|Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma\|Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer\|Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)\|Burkett´s Lymphoma\|Primary Lymphoma of the Central Nervous System	October 2011	Phase 1
NCT02284971	James Larner, MD\|Celldex Therapeutics\|University of Virginia	Prostatic Neoplasms\|Prostate Cancer	November 2014	Phase 1
NCT04941287	National Cancer Institute (NCI)	Metastatic Distal Bile Duct Adenocarcinoma\|Metastatic Gallbladder Carcinoma\|Metastatic Intrahepatic Cholangiocarcinoma\|Recurrent Distal Bile Duct Adenocarcinoma\|Recurrent Gallbladder Carcinoma\|Recurrent Intrahepatic Cholangiocarcinoma\|Stage IV Distal Bile Duct Cancer AJCC v8\|Stage IV Gallbladder Cancer AJCC v8\|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8\|Unresectable Liver and Intrahepatic Bile Duct Carcinoma	September 15, 2021	Phase 2
NCT03307746	University Hospital Southampton NHS Foundation Trust\|University Hospital Plymouth NHS Trust\|The Christie NHS Foundation Trust\|Oxford University Hospitals NHS Trust\|Celldex Therapeutics\|Cancer Research UK	B Cell Lymphoma	November 23, 2017	Phase 1\|Phase 2
NCT02386111	Celldex Therapeutics	Carcinoma, Renal Cell\|Kidney Diseases\|Kidney Neoplasms\|Urogenital Neoplasms\|Urologic Diseases\|Urologic Neoplasms\|Neoplasms\|Neoplasms by Histologic Type\|Clear-cell Metastatic Renal Cell Carcinoma	May 2015	Phase 1
NCT03688178	Gary Archer Ph.D.\|Celldex Therapeutics\|Duke University	Glioblastoma	August 26, 2020	Phase 2
NCT02335918	Celldex Therapeutics\|Bristol-Myers Squibb	Squamous Cell Carcinoma of the Head and Neck (SCCHN)\|Ovarian Carcinoma-Enrollment Completed\|Colorectal Cancer (CRC)-Enrollment Completed\|Renal Cell Carcinoma (RCC) (Phase ll Only)\|Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed	January 2015	Phase 1\|Phase 2
NCT03038672	National Cancer Institute (NCI)	ALK-Positive Large B-Cell Lymphoma\|Burkitt-Like Lymphoma With 11q Aberration\|Diffuse Large B-Cell Lymphoma Activated B-Cell Type\|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation\|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type\|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|EBV-Positive Mucocutaneous Ulcer\|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Intravascular Large B-Cell Lymphoma\|Large B-Cell Lymphoma With IRF4 Rearrangement\|Plasmablastic Lymphoma\|Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System\|Primary Effusion Lymphoma\|Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Burkitt Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements\|Recurrent Lymphomatoid Granulomatosis\|Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type\|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|Recurrent T-Cell+Histiocyte-Rich Large B-Cell Lymphoma\|Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Burkitt Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements\|Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type\|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|Refractory T-Cell+Histiocyte-Rich Large B-Cell Lymphoma	November 30, 2017	Phase 2
NCT02302339	Celldex Therapeutics	Melanoma	November 2014	Phase 2
NCT02270372	Cascadian Therapeutics Inc.\|Celldex Therapeutics\|Seagen Inc.	Advanced Breast Carcinoma\|Advanced Ovarian Carcinoma	November 2014	Phase 1
NCT04081688	Rutgers, The State University of New Jersey\|National Cancer Institute (NCI)	Refractory Lung Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8	August 21, 2019	Phase 1

Appearance

Solid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Stephen M Ansell, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020 May 12;4(9):1917-1926.